Under the transaction, Seegene will bring molecular diagnostic technology and Samsung Medical Center will bring clinical expertise, disease pathology to develop new cancer MDx tests.

As part of Seegene’s initiatives in personalized medicine, it will also develop new tests for drug resistance and Single Nucleotide Polymorphism (SNP).

Seegene’s new personalized medicine cancer tests are based on its multiplex PCR technology (DPO) and real-time PCR technology (READ) which will detect genetic mutations indicative of certain cancers.

The initial tests to be developed are for non small cell lung cancer, colon cancer, pancreatic cancer and cholangiocarcinoma.

Seegene CEO Jong-Yoon Chun said molecular diagnostics is reshaping how cancer is treated by determining which sets of genes and gene interactions affect different subsets of cancers and these tests give doctors the information needed to prescribe the right treatment.